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Simple Summary: Bowel cancer is one of the leading cancer-types in both sexes worldwide. De-
spite that most new cases and deaths occur in people aged 70 years or older, few clinical trials have
investigated the best way to administer chemotherapy in older or frail patients. The NORDIC9-study
established that moderately dose-reduced combination chemotherapy improved survival without
extra side-effects compared to full dose single drug therapy. However, many older patients with
incurable cancer seem to prefer preserved quality of life rather than longer survival. Therefore,
our aim with the current quality of life analysis of the NORDIC9-study was to assess that the more
effective chemotherapy was not at the expense of decreased quality of life. Our analyses showed that
moderately dose-reduced combination chemotherapy-maintained quality of life, physical function-
ing, and resulted in less symptoms than treatment with full dose single drug in older patients not
tolerating standard combination chemotherapy usually provided to young and fit patients.
Abstract: Quality of life data from randomized trials are lacking in older patients with metastatic
colorectal cancer (mCRC). In the randomized NORDIC9-study, reduced-dose S1+oxaliplatin (SOx)
showed superior efficacy compared to full-dose S1 monotherapy. We hypothesized that treatment
with SOx does not result in inferior quality of life. Patients with mCRC aged ≥70 years and that
were not a candidate for standard combination chemotherapy were included and randomly assigned
to receive either S1 or SOx. The EORTC QLQ-C30 questionnaire was completed at baseline, after 9,
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and 18 weeks. The primary endpoint was global Quality of Life (QoL) at 9 weeks. For statistical
analysis, a non-inferiority design was chosen applying linear mixed effects models for repeated
measurements. The results were interpreted according to statistical significance and anchor-based,
clinically relevant between-group minimally important differences (MID). A total of 160 patients aged
(median (Interquartile range (IQR))) 78 years (76–81) were included. The QLQ-C30 questionnaire was
completed by 150, 100, and 60 patients at baseline, at 9, and 18 weeks, respectively. The difference at
9 weeks in global QoL was 6.85 (95%CI—1.94; 15.65) and 7.37 (0.70; 14.05) in the physical functioning
domain in favor of SOx exceeding the threshold for MID. At 18 weeks, the between-group MID in
physical functioning was preserved. Dose-reduced combination chemotherapy may be recommended
in vulnerable older patients with mCRC, rather than full-dose monotherapy.
Keywords: older adults; metastatic colorectal cancer; chemotherapy; vulnerability; quality of life;
physical functioning; EORTC QLQ-C30; geriatric oncology
1. Introduction
Colorectal cancer (CRC) predominantly affects older adults [1]; 56% of incidence and
68% of mortality occur in patients aged ≥65 years [2]. In the older population [3], comor-
bidities, impaired organ function, and geriatric-syndromes (e.g., fall-tendency, osteoporosis,
urinary incontinence) are frequently present resulting in decreased physiological reserves,
called vulnerability [4,5]. Vulnerability affects treatment outcomes due to compromising
standard treatment approach [6], thus, in the case of chemotherapy, monotherapy and/or
dose-reduction are commonly applied. The optimal approach regarding palliative systemic
treatment in older vulnerable patients with metastatic colorectal cancer (mCRC) remains
unclear. The randomized NORDIC9-study explored this by including patients with mCRC
aged ≥70 years and that were not a candidate for standard treatment, by comparing
reduced-dose combination chemotherapy with S1+oxaliplatin (SOx) or full-dose monother-
apy (S1) (Teysuno, Taiho Pharmaceutical Co. Ltd., Tokyo, Japan). The primary results
established that SOx resulted in significantly improved progression-free survival (PFS)
(SOx; 6.2 vs S1; 5.3 months, hazard ratio: 0.72 (95%CI: 0.52–0.99), p = 0.047). Additionally,
patients treated with SOx experienced less toxicity, and fewer hospitalizations, compared
to S1 [7].
When the NORDIC9-study was designed [8], we aimed for prolonged PFS with
reduced-dose combination therapy, though somewhat higher risk of adverse events due
to the combination of cancer drugs was predicted. Therefore, we also evaluated patient-
reported health-related quality of life (QoL) and physician-reported functioning indicated
as Eastern Cooperative Oncology Group Performance Status (ECOG PS).
Only little is known about QoL, functional status, and symptom burden in vulnerable
older patients with mCRC receiving palliative chemotherapy. Oncologists are usually
interested in traditional tumor-centered endpoints used in randomized controlled trials
(RCTs) of cancer drugs [9–11]. Overall survival (OS) is considered as the gold standard
primary endpoint of efficacy in RCTs [9]. When several treatment lines are available, mea-
suring OS may be challenging, therefore, surrogate outcomes for OS like progression-free
survival and response rates have been widely used. Whether these surrogate outcomes are
valid for OS or relevant markers for expanded length of survival or QoL, is questionable.
Undoubtedly, if a treatment results in prolonged OS and less toxicities, thus, showing
clear benefits, measuring QoL from a patient-perspective may be less meaningful [12,13].
When two treatment options gain the same OS benefit, though, with one of them having
more adverse events, choosing the better option is easy for the physicians and patients.
In contrast, when the PFS benefit only slightly differs between treatment arms or between
active treatment and placebo/best supportive care, with differences in toxicities, measuring
QoL is important [14]. In this case, patient-centered QoL data may add important informa-
tion when patients and caregivers are involved in shared decision-making. Furthermore,
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an important aspect of palliative treatment is that QoL tends to worsen across treatment
lines due to disease progression, increasing tumor burden, and cumulative toxicities [15];
therefore, QoL becomes increasingly important through the continuum of care.
Despite that incidence and mortality rates top in adults aged ≥70 years, older patients
with cancer are underrepresented in RCTs [16–20]. The older population is generally treated
based on extrapolated data from highly selected younger and healthier cohorts; however,
the same drugs may be less effective and more toxic in older individuals having comor-
bidities and impaired organ function. In addition, many older patients with cancer tend to
prioritize improvement or preservation of QoL [21–23], rather than prolonged survival.
RCTs addressing QoL and patient-centered endpoints have long been desired by
patients [24,25], by researchers and physicians [26–30], the leading cancer societies [31,32]
and by regulatory authorities [19,33]. However, QoL or other patient-centered endpoints
are either not included in RCTs of cancer drugs at all [10,11], or if they are, the results
are often insufficiently reported due to methodological and practical issues [34]. In a
systematic review of phase III CRC trials conducted between 2012 and 2018, Lombardi and
colleagues found that 61% of the trials did not include QoL as endpoint [10]. In 39% of the
trials including QoL among endpoints in their primary publication, QoL data were not yet
reported. In RCTs investigating treatment options in the metastatic setting, where attention
to QoL is of particular interest due to limited life expectancy, QoL data were not available in
two-thirds of trials. This stresses the importance of appropriate conducting and reporting
of RCTs regarding patient-centered endpoints.
The overarching objective of the present study was to investigate whether prolonged
PFS with reduced-dose combination chemotherapy comes at the expense of poorer QoL
and physical functioning. We hypothesized that treatment with reduced-dose SOx might
result in inferior QoL and physical functioning compared to treatment with full-dose
S1 monotherapy.
2. Materials and Methods
2.1. Study Design, Participants, and Interventions
The NORDIC9-study was a prospective, randomized open-label phase II multi-center
study including older vulnerable patients aged ≥70 years with mCRC that were not
candidates for standard combination chemotherapy. Participants were recruited from
23 centers in four Nordic countries. Detailed protocol, study design including CONSORT
flow diagram, findings of the primary endpoint, and several secondary endpoints have
been published [7,8]. National ethical committees in all countries approved the study,
which was conducted according to the Declaration of Helsinki and Good Clinical Practice
guidelines. The NORDIC9-trial was registered at EudraCT (reg. no. 2014-000394-39).
The current manuscript conforms to the CONSORT 2010 statement for reporting RCTs
with patient-reported outcomes as primary or secondary outcomes [35,36]. A statistical
analysis plan, including pre-specified thresholds for clinically relevant between-group
minimal important differences (MID), was prepared prior to analyses and made available
online (https://portal.findresearcher.sdu.dk/da/publications/statistical-analysis-plan-
for-nordic9-study-quality-of-life-analy, accessed on 9 March 2021), thus, securing trans-
parency and reproducibility.
2.2. Interventions
Patients were randomly assigned (allocation ratio 1:1) to receive either reduced-dose
SOx (S1 20 mg/m2 orally twice daily on days 1–14 + oxaliplatin 100 mg/m2 intravenously
on day 1, q3w (once every 3 weeks)) or full-dose S1 (30 mg/m2 orally twice daily on
days 1–14, q3w). Dose modification was allowed according to the treatment protocol.
The addition of bevacizumab (7.5 mg/kg intravenously, q3w) was optional at the discretion
of the treating physician, but the decision was required before randomization. Evalua-
tion of response was planned after every three cycles. Patients were treated until disease
progression/death or unacceptable toxicities, whichever occurred first.
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2.3. Outcomes
2.3.1. Patient-Reported Outcomes
Patient-reported outcomes (PRO) on QoL were assessed with the European Organiza-
tion for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 version
3.0 (EORTC QLQ-C30) [37]. The EORTC QLQ-C30 was chosen as it is widely applied in
QoL research and extensively used in patients with solid cancer. The EORTC QLQ-C30
contains a global health scale, five functioning scales (physical, role, cognitive, emotional,
and social functioning), three symptom scales (fatigue, nausea and vomiting, and pain),
and six single items (appetite loss, diarrhea, dyspnea, constipation, insomnia, and financial
impact). The questionnaire asks about the last one-week time frame at completion and
uses a four-point response format (“not at all”, “a little”, “quite a bit”, and “very much”).
The only exception is the global health scale using a seven-point response format ranging
from “very poor” to “excellent”. The different scale and item scores are linearly trans-
formed to a score between 0 and 100 according to the scoring manual [38]. For global QoL
and the functioning scales, a higher score indicates better outcomes, for symptom scales,
a higher score reveals more prominent symptoms.
2.3.2. Physician-Reported Physical Functioning
Physician-reported outcomes of physical functioning were assessed through the ECOG
PS. The ECOG PS score has six possible values where 0 means that the patient is “fully
active, able to carry on all pre-disease performance without restriction” and a score of
5 means that the patient is “dead”. The ECOG PS is the most frequently used clinical score
in oncology daily practice and research.
2.4. Data Administration and Timing of Assessments
Patient-reported and physician-reported data were collected at the time of randomiza-
tion (baseline), after 9-, and 18-week follow-ups, corresponding to the administration of
three and six cycles of chemotherapy. For the EORTC QLQ-C30, patients self-completed
the questionnaire in paper-based versions where after it was collected by qualified study
nurses and stored in patient documentation at the clinical research units. For the ECOG PS,
physicians noted the score at the time of the clinical visit and stored it in the participants’
electronic medical record.
2.5. Data Compliance
Compliance of the patient-reported outcomes was calculated using the proportion
of randomized patients with completed questionnaires and the proportion of patients
expected to complete questionnaires (alive and still on study) at all scheduled visits (at
9-week and 18-week follow-ups).
2.6. Endpoints
PRO objectives, hypotheses, and analyses were pre-specified in a statistical analysis
plan prior to data analyses.
2.6.1. Primary Endpoint
The primary endpoint of the current analyses was to test the hypothesis that treatment
with reduced-dose SOx is not inferior to full-dose S1 in terms of affecting global QoL. We
did this by comparing the impact of SOx vs. S1 on changes in the global QoL domain as
assessed by the questionnaire from randomization to the 9-week follow-up. We choose to
compare the 9-week follow-up scores to baseline, because in patients with considerable
tumor load, the first two months are essential for whether an objective response or disease
stabilization is obtained or not. Moreover, toxicity generally occurs at the initiation of the
treatment, thus, both factors may alter global health.
While recognizing that the value of using the global QoL domain as primary out-
come in clinical trials investigating mCRC has been questioned due its low sensitivity
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to changes [39], the effect of palliative chemotherapy on global QoL has not yet been
extensively studied in older vulnerable patients with cancer. We strongly believed this
to be an important patient-centered outcome in the NORDIC9-study; the global QoL do-
main reflects the patients’ self-perceived general health and well-being, and these aspects
are often prioritized by older patients with incurable cancer and limited life expectancy,
rather than prolonged OS [21–23].
2.6.2. Secondary Endpoints
Key Secondary Objectives
This included explorative analyses of the effects of SOx relative to S1 on other clinically
important patient-reported outcome measurements in the following EORTC QLQ-C30
subscales: (1) physical functioning, (2) role functioning, and (3) social functioning from
baseline to the 9-, and 18-week follow-ups.
We selected domains of functioning as these were considered to play a key role in
older patients regarding the maintenance of their general physical and mental well-being.
We hypothesized that SOx would not result in inferior outcomes compared to S1.
Other Secondary Objectives
Given the toxicity profile of the applied cytotoxic agents and the adverse events re-
ported in the primary publication of the NORDIC9-study [7], we also aimed to perform
hypothesis generating explorative analyses on the difference between the two treatment
arms from baseline to 9-, and 18-week in the following EORTC QLQ-C30 symptom do-
mains and single items: (1) fatigue, (2) dyspnea, (3) nausea and vomiting, (4) diarrhea,
and (5) pain.
We hypothesized that patients receiving S1 full-dose monotherapy would experience
lower toxicity but may be higher symptom burden due to less efficacy compared to SOx.
Furthermore, the risk of deterioration in physician-reported physical functioning
specified by the ECOG PS score at the 9-week follow-up was established. We hypothesized
that the risk of deterioration was higher in patients receiving SOx compared to S1.
2.7. Statistical Consideration and Analysis Metrics
Formal sample size calculation for the PRO data was not performed. Hence, the
current sample follows the sample size needed for the primary endpoint of the NORDIC9-
study [7]. The current analyses of patient-centered outcomes were based on all randomized
patients receiving ≥1 dose of chemotherapy and completing at least one QoL assessment
(n = 150), while the physician-reported outcome, risk of deterioration based on ECOG PS
was conducted on the intention to treat (ITT) population of the randomized trial (n = 160).
2.7.1. For the Patient-Reported Outcomes
The primary statistical model for the PROs consisted of linear mixed effects model
for repeated measures (MMRM) including all PRO assessments (e.g., baseline, 9 weeks,
and 18 weeks). This allowed us to compare the average treatment effect of reduced-dose
SOx vs. full-dose S1.
These analyses were performed as non-inferiority analyses reporting coefficients with
95% confidence intervals for mean differences and comparing with between-group mean
minimal important differences (MID) as reported by Musoro et al. [40]. As it is not assured
that the baseline PRO measurements were performed before the patient and healthcare
professionals were informed about the result of the randomization, the treatment effect
was included at baseline. Methodological discussion of this consideration can be found
elsewhere [41].
To provide easily interpretable estimates of the probabilities of non-inferiority and
superiority we provided a sensitivity analysis fitted a Bayesian linear mixed effects model
(using Markov Chain Monte Carlo, MCMC) with weakly informative symmetric priors (N
(0,10000)) for regression coefficients and weakly informative (IGamma(0.01,0.01)) priors for
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variance components. This model resulted in posterior probabilities of superiority, non-
inferiority, equivalence, and inferiority, providing straightforward comparison between
possible scenarios of treatment effects among arms.
2.7.2. For the Physician-Reported Outcomes
Deterioration of ECOG PS score from baseline to 9-, and 18-week follow-ups was
defined as a ≥1-point decline from baseline and was analyzed using logistic regression.
In the main analysis, discontinuation of the study participation for any reason was regarded
as deterioration of performance. Two sensitivity analyses (A and B) were conducted. In sen-
sitivity analysis “A” only discontinuation due to death was considered as deterioration,
while patients who left the study for other reasons were excluded. In sensitivity analysis
“B” only observed ECOG PS were used to define deterioration and any patients who left
the study were excluded.
2.8. Data Analysis
All data were analyzed in STATA v16 (StataCorp LLC, College Station, TX, USA),
p-values ≤ 0.05 were considered statistically significant and estimates were reported with
95% confidence intervals (95%CI).
2.9. Adjustment for Multiplicity
As only global QoL was considered as the primary endpoint along with a pre-specified
primary data assessment time point, and other outcomes were considered secondary and
supportive to the primary outcome, no adjustment for multiplicity was performed.
2.10. Missing Data, Sensitivity Analyses, and Robustness
Missing data in the PRO analyses were handled by restricted maximum likelihood es-
timation in the linear mixed effects model including all answered questionnaires. This anal-
ysis assumed missing at random questionnaires, although this assumption could not be
checked in our study. Missing data in the ECOG PS analysis were handled by the two
pre-specified sensitivity analyses (see above).
Acceptable fulfillment of model assumptions was investigated by normal quantile-
quantile plots for residuals and random effects in the linear mixed models, in case of
deviations, nonparametric bootstrapping with 1000 repetitions was performed.
Performance of the MCMC algorithm applied in the Bayesian models was investigated
by diagnostic plots (trace, autocorrelation, and posterior kernel density).
Goodness of fit of the logistic regression model was investigated by Hosmer–Lemeshow’s test.
2.11. Interpretation
In general, each PRO domain was interpreted according to clinically relevant MID
using guidelines for between-group differences and changes over time [40,42].
2.11.1. Primary Outcome
For the global QoL domain, the result was interpreted according to the anchor-based
MID for between-group differences as reported by Musoro et al. [40], who established
MIDs specifically in patients with mCRC. Based on the principles related to non-inferiority
designs we pre-specified that a 95% CI excluding negative differences between groups of
greater than −8.13 points (the mean MID for deterioration) in global QoL was interpreted
as indicating the absence of a clinically meaningful inferiority difference.
2.11.2. Key Secondary Patient-Reported Outcomes
For functioning domains (physical functioning, role functioning, and social function-
ing), symptom domains, and single items (fatigue, nausea and vomiting, diarrhea, and
pain) the results were interpreted according to the anchor-based mean MID for deteri-
oration by between-group differences according to Musoro et al. [40]. However, as the
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symptom domain of dyspnea was not included in [40], this domain was interpreted accord-
ing to the medium between-group MID score (at least 9 points difference) established by
Cocks et al. [42].
2.11.3. Clinician-Reported Outcome
Risk of deterioration was compared between the two treatment groups according to
the analysis specified above.
3. Results
3.1. Patient Population
From March 2015 to October 2017, 160 patients with a median age of 78 years (in-
terquartile range 76–81) were included in the NORDIC9-study, of whom 150 were available
for the QoL analysis (Figure 1). Patient and disease characteristics and baseline score of
QLQ-C30 domain scores were well balanced between the treatment arms as shown in
Tables 1 and 2.
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Table 1. Baseline demographic and clinical characteristics of patients included in the quality of life analyses of the
randomized NORDIC9-study.
Characteristics
Data Presented as Mean or n (%) as Appropriate
NORDIC9-Study Treatment Arms









Mean age in years (SD) 78.4 (4.0) 77.8 (3.7)
70–74 years 14 (18%) 17 (24%)
75–79 years 36 (46%) 34 (48%)
≥80 years 29 (37%) 20 (28%)
Gender
Female 39 (49%) 36 (51%)
Male 40 (51%) 35 (49%)
ECOG Performance status *
0 31 (40%) 22 (31%)
1 32 (41%) 35 (49%)
2 15 (19%) 14 (20%)
Location of primary tumor *
Left sided colon 25 (32%) 25 (35%)
Right sided colon 27 (35%) 20 (28%)
Rectum 23 (29%) 18 (25%)
Transverse colon 3 (4%) 8 (11%)
Surgery for primary tumor
No 36 (46%) 32 (45%)
Yes 43 (54%) 39 (55%)
Prior adjuvant chemotherapy
Yes 18 (23%) 10 (14%)
No 61 (77%) 61 (86%)
Presentation at diagnosis
Synchronous 29 (37%) 30 (42%)
Metachronous 50 (63%) 41 (58%)
Number of metastatic sites
1–2 45 (57%) 45 (63%)
3≤ 34 (43%) 26 (37%)
Sites of metastatic disease
Liver 55 (70%) 40 (56%)
Lung 33 (42%) 27 (38%)
Lymph nodes 41 (52%) 28 (39%)
Peritoneum 11 (14%) 28 (39%)
Bone 3 (4%) 3 (4%)
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Table 1. Cont.
Characteristics
Data Presented as Mean or n (%) as Appropriate
NORDIC9-Study Treatment Arms









No 72 (91%) 64 (90%)
Yes 7 (9%) 7 (10%)
RAS mutation status
Wild type 29 (37%) 28 (39%)
Mutant 29 (37%) 26 (37%)
Unknown 21 (27%) 17 (24%)
BRAF mutation status
Wild type 43 (54%) 36 (51%)
Mutant 10 (13%) 10 (14%)
Unknown 26 (33%) 25 (35%)
Self-reported weight-loss >5% within the last 2
months
Yes 55 (70%) 59 (83%)
No 24 (30%) 12 (17%)
* One missing item.
Table 2. Mean values of the European Organization of Research and Treatment of Cancer QLQ-C30 scores per domains by
treatment group and time points. The selected domains are of special interest in older patient with mCRC. No statistically








Domains S1 SOx S1 SOx S1 SOx
Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Global QoL 66.35 (22.31) 65.38 (20.92) 62.50 (20.18) 67.88 (22.01) 69.79 (23.16) 64.51 (21.38)
Physical functioning 81.60 (16.30) 77.11 (19.00) 73.65 (20.42) 77.60 (19.06) 72.32 (21.69) 77.90 (18.65)
Social functioning 83.12 (24.98) 82.39 (23.04) 82.37 (25.23) 84.03 (17.52) 83.33 (28.08) 83.95 (19.87)
Role functioning 80.38 (25.28) 77.23 (27.64) 73.08 (29.55) 75.53 (23.79) 78.28 (26.51) 80.25 (20.69)
Fatigue 32.91 (23.98) 34.98 (23.30) 40.49 (22.85) 37.27 (22.28) 38.38 (27.23) 33.33 (18.49)
Nausea and vomiting 4.85 (10.04) 6.34 (15.00) 7.69 (12.98) 11.11 (16.25) 8.59 (13.26) 7.41 (11.63)
Diarrhea 22.36 (31.45) 18.78 (25.65) 25.33 (31.99) 22.22 (26.93) 19.19 (26.39) 14.10 (21.44)
Pain 20.46 (26.55) 12.44 (19.86) 13.78 (21.82) 11.11 (20.15) 13.13 (25.94) 17.28 (24.67)
Dyspnea 16.24 (22.63) 16.43 (23.82) 25.00 (26.30) 12.50 (21.33) 20.20 (21.95) 12.82 (16.54)
3.2. Compliance
The EORTC QLQ-C30 questionnaire was completed by all 150 (100%) patients at base-
line. Patients alive and still on-study at 9-week and 18-week follow-ups, thus constituting
the proportion of number of patients expected to return a questionnaire, were 132 and 114,
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respectively. Questionnaire compliance at 9 weeks was 76% (100/132) and 52% (60/114) at
18 weeks. Compliance was balanced between groups at all assessment time points.
Most missing questionnaires were lacking due to a procedural error; one site including
36 patients completed EORTC QLQ-C30 only at baseline.
3.3. Primary Endpoint
The between-group difference in global QoL was 6.85 (95%CI -1.94; 15.65) at 9 weeks
in favor of SOx (SOx: 2.63 (−4.84; 10.11), S1: −4.22 (−9.16; 0.72), p = 0.127). Despite this
being non-significant, the difference exceeded the pre-specified threshold for MID between
groups. At 18 weeks, the difference was neither statistically significant nor clinically
relevant (Table 3, Figure 2).
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Figure 2. Global QoL over time as line-diagram with 95% CI at baseline, at 9-week and at 18-week 
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3.4. Key Secondary Patient-Reported Endpoints 
In the physical functioning domain, a statistically significant between-group differ-
ence of 7.37 (0.70; 14.05) at 9 weeks was seen in favor of SOx (SOx: −0.14 (−4.73; 4.44), S1: -
7.52 (−12.23; −2.80), p = 0.03). This difference exceeded the pre-specified threshold for be-
tween-group MID. At 18 weeks, a non-significant, however clinically relevant between-
group difference of 7.88 (−1.68; 17.43) was seen in favor of the SOx group in physical func-
tioning (SOx: −2.57 (−9.50; 4.36), S1: −10.44 (−16.98; −3.91), p = 0.106). 
Regarding the domains of social and role functioning, neither statistically significant 
differences, nor clinically relevant MIDs were observed at 9 and 18 weeks (Table 3). 
3.5. Other Secondary Endpoints 
Regarding the EORTC QLQ-C30 symptom domains and single items, statistically sig-
nificant between-group difference of −11.36 (−21.18; −1.53) was seen in dyspnea at 9 weeks 
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Regarding dyspnea, clinically-relevant MID was defined according to the EORTC
evidence-based guidelines for between-group differences by Cocks et al.
3.4. Key Secondary Patient-Reported Endpoints
In the physical functioning domain, a statistically significant between-group difference
of 7.37 (0.70; 14.05) at 9 weeks was seen in favor of SOx (SOx: −0.14 (−4.73; 4.44), S1: −7.52
(−12.23; −2.80), p = 0.03). This difference exceeded the pre-specified threshold for between-
group MID. At 18 weeks, a non-significant, however clinically relevant between-group
difference of 7.88 (−1.68; 17.43) was seen in favor of the SOx group in physical functioning
(SOx: −2.57 (−9.50; 4.36), S1: −10.44 (−16.98; −3.91), p = 0.106).
Regarding the domains of social and role functioning, neither statistically significant
differences, nor clinically relevant MIDs were observed at 9 and 18 weeks (Table 3).
3.5. Other Secondary Endpoints
Regarding the EORTC QLQ-C30 symptom domains and single items, statistically
significant between-group difference of −11.36 (−21.18; −1.53) was seen in dyspnea
at 9 weeks in favor of the SOx group, which also exceeded the pre-specified threshold
for between-group MID (SOx: −3.08 (−10.18; 4.01), S1: 8.27 (1.70; 14.85), p = 0.024).
The between-group difference slightly decreased at 18 weeks, though the trend was not
altered (Table 3).
In fatigue, no statistically significant between-group difference was observed, the SOx
group experienced less fatigue, though, the between-group MID did not exceed the thresh-
old for clinical relevance at 9 weeks. At 18 weeks, clinically relevant between-group
difference of -7.54 (−20.09; 5.00) was observed in favor of SOx (SOx: 1.24 (−7.93; 10.40), S1:
8.78 (0.21; 17.36), p = 0.239) (Table 3).
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Table 3. Mean change coefficients and between-group differences with 95% confidence intervals of the EORTC QLQ-C3 domains from baseline to 9-week and 18-week follow-ups in
the two treatment arms. Anchor based clinically relevant minimally important differences (MID) in patients with colorectal cancer receiving chemotherapy according to Musoro et al.
are highlighted.
EORTC QLQ-C30
Domains Change from Baseline to 9-Week Follow-Up Change from Baseline to 18-Week Follow-Up
S1 SOx Difference S1 SOx Difference
Coefficient (95% CI) Coefficient (95% CI) Coefficient (95% CI) p-Value Coefficient (95% CI) Coefficient (95% CI) Coefficient (95% CI) p-Value



































































































p < 0.05 is considered statistically significant.
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In terms of diarrhea, nausea and vomiting, and pain, neither statistically significant
differences nor clinically relevant MID were observed during follow-up (Table 3).
3.6. Clinician-Reported Outcome
From baseline to 9 weeks of treatment, the risk of deterioration in ECOG PS was lower
in the SOx group compared to the S1 group. However, the result was not statistically
significant (Odds ratio (OR) = 0.75 (95% CI 0.40; 1.41), p = 0.366). Similar result was
observed at 18 weeks of treatment (OR = 0.88 (0.47; 1.64), p = 0.676) (Table 4). The results of
the sensitivity analyses are shown in Table 5.
Table 4. Risk of deterioration based on ECOG PS deterioration at 9-week and at 18-week follow-ups.
Risk of Deterioration at 9 Weeks 18 Weeks
OR (95% CI) p-value OR (95% CI) p-Value
Main analysis 0.75 (0.40; 1.41) 0.366 0.88 (0.47; 1.64) 0.676
Sensitivity analysis A 0.96 (0.39; 2.35) 0.924 0.73 (0.32; 1.71) 0.472
Sensitivity analysis B 1.15 (0.45; 2.92) 0.771 0.83 (0.25; 2.74) 0.762
p < 0.05 is considered statistically significant.
Table 5. ECOG PS at baseline, at 9-week and at 18-week follow-ups per treatment groups indicated as
counts and proportions. The sensitivity analyses with different imputation choices allowed utilization
of data in incomplete observations.
Baseline 9-Week Follow-Up 18-Week Follow-Up
Treatment Arms S1 SOx S1 SOx S1 SOx
Main analysis
PS = 0 31 (37%) 23 (30%) 19 (23%) 12 (16%) 16 (19%) 10 (13%)
PS = 1 35 (42%) 37 (48%) 28 (34%) 37 (48%) 20 (24%) 25 (33%)
PS = 2 15 (18%) 15 (20%) 8 (10%) 10 (13%) 4 (5%) 5 (7%)
Dropout/Missing 2 (2%) 2 (3%) 26 (31%) 18 (23%) 32 (38%) 28 (36%)
Death 0 (0%) 0 (0%) 2 (2%) 0 (0%) 11 (13%) 9 (12%)
Sensitivity analysis A
PS = 0 31 (38%) 23 (31%) 19 (33%) 12 (20%) 16 (31%) 10 (20%)
PS = 1 35 (43%) 37 (49%) 28 (49%) 37 (63%) 20 (39%) 25 (51%)
PS = 2 15 (19%) 15 (20%) 8 (14%) 10 (17%) 4 (8%) 5 (10%)
Death 0 (0%) 0 (0%) 2 (4%) 0 (0%) 11 (22%) 9 (18%)
Sensitivity analysis B
PS = 0 31 (38%) 23 (31%) 19 (35%) 12 (20%) 16 (40%) 10 (25%)
PS = 1 35 (43%) 37 (49%) 28 (51%) 37 (63%) 20 (50%) 25 (63%)
PS = 2 15 (19%) 15 (20%) 8 (15%) 10 (17%) 4 (10%) 5 (13%)
3.7. Bayesian Sensitivity Analyses
The sensitivity analyses resulted in a probability of non-inferiority of the reduced-dose
combination chemotherapy of at least 89% for all investigated EORTC QLQ-C30 domains
at 9 weeks, and at least 76% at 18 weeks. The only deviation from this was the fatigue
domain, for which the evidence of non-inferiority was only 64% and 46% at 9 and 18 weeks,
respectively (Table S1). The posterior distribution for global QoL at 9 weeks is presented in
Figure S1.
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4. Discussion
4.1. Summary of Findings
Our findings demonstrate that reduced-dose combination chemotherapy may be the
treatment of choice in older vulnerable patients with mCRC when preservation of QoL,
physical functioning, and symptom relief are important goals of the treatment. Although
non-significant, a clinically relevant between-group MID in favor of SOx was observed in
the primary endpoint, global QoL at the primary assessment time point at 9 weeks after
commencing the treatment. Additionally, a statistically significant and clinically relevant
difference in the key secondary endpoint of physical functioning in favor of SOx treatment
was seen at the primary data assessment time point. Likewise, our findings indicate
that patients treated with SOx experienced less symptom burden with clinically relevant
between-group MID in symptoms of dyspnea and fatigue at 9 weeks and at 18 weeks,
respectively. The Bayesian sensitivity analyses confirmed our findings of good evidence of
non-inferiority of the reduced-dose combination chemotherapy.
4.2. Explanations/Interpretations
Patients receiving reduced-dose SOx gained PFS benefit, experienced less toxicity [7],
and preserved global QoL and physical functioning compared to those treated with full-
dose S1 monotherapy. The difference in terms of global QoL occurred mostly due to
the deterioration in the S1 group at 9 weeks, while global QoL scores in the SOx group
remained stable during treatment. Furthermore, the S1 group experienced more prominent
symptoms most probably due to toxicity and less efficacy.
4.3. Comparison to Other Studies
Although the global QoL seems to provide beneficial information, its value and
sensitivity reflecting to the toxicity issues patients are facing during palliative treatment for
mCRC were questioned by Schuurhuizen and colleagues [43,44]. In their systematic review,
30 phase III RCTs evaluating palliative systemic treatments in patients with mCRC were
assessed based on QoL, toxicities, and primary outcomes [43]. Interestingly, in 83% of these
RCTs no difference between treatment arms was observed in terms of global QoL, although,
73% of the studies reported higher occurrence of grade 3–5 non-hematological toxicities in
the experimental arm. In 86% of these studies, against expectations [43,44], global QoL was
either not affected or improved. In 37% of studies where primary outcome was improved,
no enhancement in global QoL was observed. A reasonable question was articulated by
the authors, whether global QoL is sensitive enough and thus should be considered as a
clinically relevant endpoint. In these studies, global QoL score does not seem sensitive
enough to guide treatment selection and shared decision-making. This contrasts with our
findings in older patients showing a clinically relevant difference, thus, seems able to guide
treatment selection. It should be noted that the systematic review contained only one study
specifically designed for older patients applying exclusively the global QoL domain from
the EORTC QLQ-C30 questionnaire [45]. Furthermore, QoL improvement was defined
as “any increase between baseline and 12 weeks”, thus, scoring procedure did not follow
the official EORTC manual, and the results must be interpreted with caution. Another
explanation is that we applied cancer site specific anchor-based clinically important MID
for interpretation of our findings, making the interpretation more specific to the group of
patients with mCRC.
Another option might be the application of risk of deterioration or time to deterioration
as endpoint, based on clinician-reported outcomes, like ECOG PS; however, ECOG PS and
oncologists’ clinical judgement have shown poor association compared to a systematic
in-depth evaluation, called comprehensive geriatric assessment (CGA) in older patients
with cancer [46,47]. Hence, ECOG PS might not be appropriate to reveal impairments
which may be recognized through CGA and do affect QoL. The solution may be to collect
data from the older population through randomized clinical trials dedicated and designed
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to this specific group of patients [26–30]; furthermore, widespread implementation of the
CGA for patient stratification is desired [48–50].
4.4. Methodological Considerations-Strengths and Limitations
A major strength of our study is that the statistical analysis plan was developed and
made available online before the analyses were conducted securing transparency and
reproducibility. In addition, to the best of our knowledge, our study was the first applying
the MID for interpreting the EORTC QLQ-C30 for objective comparison and interpretation
of QoL domains in older patients with mCRC treated with chemotherapy [40]. Using MID
may allow easier understanding of the potential benefits and harms of the treatment, hence,
focusing on PROs and including them in shared decision-making process will thus be
more applicable in the clinical practice. Finally, we included vulnerable older patients with
mCRC in a multicenter study. This important group of patients has not previously been
extensively investigated and we believe our results contribute significantly to this field.
It must be acknowledged, that our dataset has some limitations due to missing items
and questionnaires; however, in older vulnerable adults with metastatic cancer the attrition
leading to missing data is inevitable considering the advanced cancer and vulnerabilities
these patients are presented with. Patients with most symptoms having lowest baseline
scores are at highest risk for drop-out, thus, changes in MIDs might be biased at 9 and
18 weeks. It is expected at patient with higher baseline scores or obtaining response will
complete the questionnaires during the treatment course, which reflects to the general per-
ception of QoL of patients who were less vulnerable or derived benefit from the treatment.
Notably, the number of missing items and questionnaires due to patient drop-out is consis-
tent with previously reported data from a similar population [51]. To deal with missing
items and drop-out appropriately, we strictly followed the EORTC scoring manual and
carried out sensitivity analyses with different imputation choices for the ECOG secondary
outcome allowing utilization of data in incomplete observations. Missing questionnaires
due to protocol deviation and procedural errors emphasizes the importance of appropriate
conductance of RCTs.
5. Conclusions
The NORDIC9-study established that reduced-dose combination chemotherapy in
addition to its increased efficacy did not result in inferior QoL compared to the reference
treatment with full-dose monotherapy in older patients not fit for standard combination
treatment. Thus, the treatment of choice in older vulnerable patients with mCRC should be
reduced-dose combination chemotherapy when preservation of QoL, physical functioning,
and symptom relief are important goals of the treatment.
6. Future Perspectives/Implication
Many older patients with cancer tend to prioritize improvement or preservation of
QoL rather than overall survival. Therefore, patient-centered endpoints including patient
preferences and shared decision-making with a focus on preservation and improvement of
physical and mental wellbeing should be the primary or co-primary endpoints of future
clinical trials in older patients with cancer, rather than PFS and surrogate outcomes widely
applied in medical oncology. Likewise, for appropriate patient stratification, the concept of
CGA should be incorporated and guide treatment and supportive care interventions.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/cancers13112604/s1, Figure S1: Posterior distribution of difference in global QoL at 9-week
follow-up, Table S1: Bayesian analysis of EORTC QLQ-C30 domain measurements reporting the
(posterior) probability of superiority (respectively, non-inferiority/equivalence/inferiority) of SOx
compared to S1.
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